These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16723628)

  • 1. ADHD drugs and cardiovascular risk.
    Anders T; Sharfstein S
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16723628
    [No Abstract]   [Full Text] [Related]  

  • 2. ADHD drugs and cardiovascular risk.
    Rappley MD; Moore JW; Dokken D
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract]   [Full Text] [Related]  

  • 3. ADHD drugs and cardiovascular risk.
    Nissen SE
    N Engl J Med; 2006 Apr; 354(14):1445-8. PubMed ID: 16549404
    [No Abstract]   [Full Text] [Related]  

  • 4. To box OR NOT TO box.
    Newstadt M
    J Ky Med Assoc; 2006 Aug; 104(8):344-5. PubMed ID: 16939037
    [No Abstract]   [Full Text] [Related]  

  • 5. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E
    CMAJ; 2006 Jul; 175(1):29. PubMed ID: 16772535
    [No Abstract]   [Full Text] [Related]  

  • 6. ADHD black box warning: how concerned should we be?
    Cruz R; Kutscher EC
    S D Med; 2007 Feb; 60(2):63, 65. PubMed ID: 17390569
    [No Abstract]   [Full Text] [Related]  

  • 7. Stimulant medications and attention deficit-hyperactivity disorder.
    Cohen AL; Jhung MA; Budnitz DS
    N Engl J Med; 2006 May; 354(21):2294-5. PubMed ID: 16723627
    [No Abstract]   [Full Text] [Related]  

  • 8. Debate over warnings for ADHD stimulants.
    Child Health Alert; 2006 Apr; 24():1. PubMed ID: 16673500
    [No Abstract]   [Full Text] [Related]  

  • 9. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM; Friedman RA; Knilans TK; ;
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract]   [Full Text] [Related]  

  • 11. ADHD treatment and the risk of substance abuse.
    Sircy RA; Stojanoski A
    Nurse Pract; 2008 Apr; 33(4):33-6. PubMed ID: 18388552
    [No Abstract]   [Full Text] [Related]  

  • 12. ADHD drugs and cardiovascular risk.
    Wojnowski L
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729376
    [No Abstract]   [Full Text] [Related]  

  • 13. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.
    Gerhard T; Winterstein AG; Olfson M; Huang C; Saidi A; Crystal S
    Pharmacoepidemiol Drug Saf; 2010 May; 19(5):457-64. PubMed ID: 20232490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
    Vetter VL; Elia J; Erickson C; Berger S; Blum N; Uzark K; Webb CL; ;
    Circulation; 2008 May; 117(18):2407-23. PubMed ID: 18427125
    [No Abstract]   [Full Text] [Related]  

  • 15. A reply to critics of using stimulants to treat attention deficit hyperactivity disorder.
    Pliszka SR
    Tex Med; 1991 Apr; 87(4):84-7. PubMed ID: 1674631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medication for ADHD and the risk of cardiovascular mortality].
    Kalverdijk LJ; Buitelaar JK; van der Gaag RJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2283-4; author reply 2284. PubMed ID: 17078147
    [No Abstract]   [Full Text] [Related]  

  • 17. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk.
    Gadow KD; Sverd J
    J Dev Behav Pediatr; 1990 Oct; 11(5):269-71; discussion 272. PubMed ID: 1979565
    [No Abstract]   [Full Text] [Related]  

  • 18. Stimulants for kids with ADHD--how to proceed safely.
    Ken Mehta S; Jacobs I
    J Fam Pract; 2014 Feb; 63(2):E1-5. PubMed ID: 24527478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA ponders cardiovascular risks of ADHD drugs.
    Young D
    Am J Health Syst Pharm; 2006 Mar; 63(6):492-4. PubMed ID: 16522874
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.